Zobrazeno 1 - 10
of 61
pro vyhledávání: '"S. P. Protsenko"'
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 1, Pp 141-150 (2023)
Objective. To present the available data regarding the tolerance of immune checkpoint inhibitors (ICIs) in cancer patients with concurrent HIV.Material and Methods. A literature search was conducted in the electronic databases PubMed, Cochrane Librar
Externí odkaz:
https://doaj.org/article/6d16b8cc57244caf8ff4d89805adc006
Autor:
E. A. Ulrikh, E. L. Dikareva, A. D. Dzharbaeva, O. A. Zhamborova, T. M. Pervuninа, E. V. Komlichenko, S. A. Protsenko, G. M. Teletaeva, O. A. Li, A. S. Artemyeva, I. A. Mashenko, G. F. Kutusheva, T. Yu. Semiglazova, А. F. Urmancheeva
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 3, Pp 112-117 (2022)
Trophoblastic neoplasias are rare tumors, accounting for less than 1 % of malignant neoplasms of the female genital tract. Trophoblastic tumors associated with developing pregnancy are extremely rare. The article presents the successful experience of
Externí odkaz:
https://doaj.org/article/aca41088b8854a62a107554883917393
Autor:
E. A. Degtiareva, S. A. Protsenko, E. N. Imyanitov, G. M. Teletaeva, D. Kh. Latipova, A. I. Semenova, A. V. Novik
Publikováno v:
Сибирский онкологический журнал, Vol 21, Iss 5, Pp 162-167 (2022)
Background. The development of unique immune-related adverse events (irAEs) is a known hallmark of immunotherapy. Generally, such complications occur during the first 3–6 months of immunotherapy, however, the experience with immune checkpoint inhib
Externí odkaz:
https://doaj.org/article/cfda88e2472c45b3aad1f09ca00782ed
Autor:
M. S. Knyazeva, V. A. Zagoruiko, A. V. Khokhlova, I. V. Nazarova, A. V. Shalaev, E. I. Sidina, L. M. Zabegina, A. S. Artemyeva, A. K. Nosov, S. A. Protsenko, A. V. Malek
Publikováno v:
Успехи молекулярной онкологии, Vol 9, Iss 1, Pp 20-32 (2022)
Introduction. Testicular germ cell tumor is a relatively rare disease. Its high social significance is due to the fact that this pathology occurs in young patients. The standard schemes of polychemotherapy determine the potential possibility of effec
Externí odkaz:
https://doaj.org/article/32a52527f21b436d81dd21b6bdcf1204
Publikováno v:
Advanced Engineering Research, Vol 21, Iss 3, Pp 222-230 (2021)
Introduction. It is noted that the use of adaptive grids in calculations makes it possible to improve the accuracy and efficiency of computational algorithms without increasing the number of nodes. This approach is especially efficient when calculati
Externí odkaz:
https://doaj.org/article/570acd43c7324c4497faea94b3f1b035
Autor:
M. I. Sluzhev, V. V. Semiglazov, T. Yu. Semiglazova, E. V. Tkachenko, S. A. Protsenko, D. Kh. Latipova, S. V. Kondratev, N. A. Brish, Yu. V. Alekseeva, A. M. Belyaev
Publikováno v:
Сибирский онкологический журнал, Vol 20, Iss 5, Pp 149-161 (2021)
Challenges in cancer detection, prognosis and management are currently being solved by determining circulating tumor DNA (ctDNA). The assessment of this marker has acquired particular importance in metastatic colorectal cancer (mCRC), the systemic tr
Externí odkaz:
https://doaj.org/article/7316d304819a481aadb5af0b7ed88cbc
Publikováno v:
Сибирский онкологический журнал, Vol 20, Iss 2, Pp 37-45 (2021)
Purpose of the study: to assess whether the determination of the grade of dNA damage in the blood lymphocytes of patients with metastatic melanoma can be a criterion for assessing the effectiveness of therapy. Material and Methods. The grade of dNA d
Externí odkaz:
https://doaj.org/article/4a3f0e29ca4549f8a57b19b246e30aca
Autor:
V. F. Semiglazov, A. I. Tseluiko, I. A. Baldueva, T. L. Nekhaeva, A. S. Artemyeva, A. G. Kudaybergenova, S. A. Protsenko, A. V. Novik, V. V. Semiglazov, R. V. Donskikh, T. Yu. Semiglazova, R. S. Pesotskiy, V. S. Apollonova, P. V. Krivorotko, A. M. Belyaev
Publikováno v:
Медицинский совет, Vol 0, Iss 4, Pp 248-257 (2021)
Immuno-oncology is a rapidly developing field in medicine. Drug combination therapies have already been studied in many clinical trials of different types of tumours. In recent years, a checkpoint inhibition therapy with monoclonal antibodies that ta
Externí odkaz:
https://doaj.org/article/e7ba8a2e3c3d43869df41d7cfecb6bbe
Autor:
G. M. Teletaeva, E. A. Ulrikh, D. Kh. Latipova, A. I. Semenova, E. V. Levchenko, D. G. Ulrikh, I. V. Berlev, T. Yu. Semiglazova, S. A. Protsenko, A. F. Urmancheeva
Publikováno v:
Опухоли женской репродуктивной системы, Vol 16, Iss 3, Pp 67-71 (2021)
Gestational trophoblastic disease is a rare tumor highly sensitive to systemic drug therapy. The standard regimens of chemotherapy of I and II lines for patients in the high-risk group for gestational trophoblastic disease are the EMA-CO, EMA-EP and
Externí odkaz:
https://doaj.org/article/60736af458fb4801999c1654f4987569
Autor:
S. A. Protsenko, E. N. Imyanitov, A. I. Semenova, D. Kh. Latipova, A. V. Novik, D. O. Yurlov, A. P. Oganesian
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 54-61 (2020)
Melanoma of the skin is one of the most aggressive malignant neoplasms. Metastatic skin melanoma has an extremely poor clinical prognosis with a high mortality rate, accounting for 80% of all deaths from skin malignancies. The approaches to the treat
Externí odkaz:
https://doaj.org/article/b0018e303c634f01befa2d7bfd783831